Drugs / CD19 hsCAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03902197 | Apr 2019 → Dec 2021 | B-cell acute lymphoblastic leukemia | Xuanwu Hospital, Beijing | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19 hsCAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03902197 ↗ |
| Modality | Cell therapy | “This cohort will be administrated by T cells transduced with lentivirus vectors expressing CD19 hsCAR” NCT03902197 ↗ |
| Route | Intravenous | “CD19 hsCAR-T will be administered by I.V. infusion” NCT03902197 ↗ |
| Target | CD19 | “This Phase II study is to evaluate the efficacy and safety of a CD19-targeting humanized selective CAR-T (CD19 hsCAR-T)” NCT03902197 ↗ |